References
- 1. Fox KAA, Metra M, Morais J, Atar D. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol. 2020;17:9-21. Epub 2019 Jul 29.10.1038/s41569-019-0233-y
- 2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477.10.1093/eurheartj/ehz425
- 3. Sorbets E, Fox K, Elbez Y, et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2019;00:1-10.
- 4. Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262-267.10.1136/bmj.38695.605440.AE
- 5. Juarez-Orozco LE, Saraste A, Capodanno D, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Heart J Cardiovasc Imaging. 2019; 20:1198-1207.10.1093/ehjci/jez054
- 6. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.10.1093/eurheartj/eht296
- 7. SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel group, multicentre trial. Lancet. 2015;385:2383-2391.10.1016/S0140-6736(15)60291-4
- 8. Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of noninvasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J. 2018;39:3322-3330.10.1093/eurheartj/ehy26729850808
- 9. Piepoli MF, Hoes AW, Agewall S, et al. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention ---amp--- Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-2381.10.1093/eurheartj/ehw106498603027222591
- 10. Booth JN III, Levitan EB, Brown TM, Farkouh ME, Safford MM, Muntner P. Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2014;113:1933-1940.10.1016/j.amjcard.2014.03.033434857624793668
- 11. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940-2948.10.1093/eurheartj/eht29523907142
- 12. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40:190-194.10.1093/eurheartj/ehy504
- 13. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213-260.10.1093/eurheartj/ehx419
- 14. Orme RC, Parker WAE, Thomas MR, et al. Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI). Circulation. 2018;138:1290-1300.10.1161/CIRCULATIONAHA.118.034790
- 15. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-1330.10.1056/NEJMoa1709118
- 16. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165.10.1093/eurheartj/ehy394
- 17. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379:250-259.10.1056/NEJMoa1803538
- 18. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511-1520.10.1056/NEJMoa1602001
- 19. Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: Network meta-analysis. BMJ. 2014;348:g3859.10.1136/bmj.g3859
- 20. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a doubleblind, randomised controlled trial. Lancet. 2018;391:31-40.10.1016/S0140-6736(17)32714-9
- 21. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:312-319.10.1001/archinternmed.2011.148422371919
- 22. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation. 2013;127:769-781.10.1161/CIRCULATIONAHA.112.13196123325526
- 23. International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA). https://professional.heart.org/professional/ScienceNews/UCM_505226_ISCHEMIA-Clinical-Trial-Details.jsp (06 December 2019)